Meditrina Welcomes Senior Vice President of Global Sales to Lead Expansion Efforts and Manage Rapid Growth
SAN JOSE, Calif., May 13, 2024 /PRNewswire/ -- Meditrina, a leader in gynecologic medical devices, announced today the expansion of its leadership team with the hiring of Ray Gerena, as Senior Vice President of Global Sales. With an extensive career in medical device sales, including a role as Vice President of Sales at Hologic for the GYN surgical division, and a proven track record of driving exponential growth, Ray brings a wealth of expertise and strategic vision to Meditrina's dynamic team.
Joining Meditrina at a pivotal juncture, Ray steps into his role following a remarkable period of achievement. The company recently marked a record sales month, nearing cash flow positivity and received approval of UKCA Mark, and CE Mark in accordance with Regulation (EU) 20147/745. As the global demand for modern hysteroscopy solutions continues to soar, Meditrina remains at the forefront of transforming women's healthcare with its integrated hysteroscopy system designed for diagnostic and therapeutic gynecology procedures.
"We are delighted to welcome Ray to the team," said Csaba Truckai, Founder and CEO of Meditrina. "His expertise and proven ability to drive results will be instrumental in propelling our growth trajectory and further establishing Meditrina as a key provider of transformative solutions in women's health."
In his new role, Ray will leverage his extensive industry experience to accelerate Meditrina's sales initiatives on a global scale. His strategic leadership and unwavering commitment to customer satisfaction will play a pivotal role in driving market penetration and fostering strategic partnerships with healthcare providers worldwide.
In addition to driving sales growth, Ray will oversee the management of Meditrina's rapidly expanding salesforce. This entails implementing scalable strategies to optimize team performance, fostering a culture of continuous learning and development, and providing the necessary resources and support to empower sales representatives to excel in their roles.
Ray expressed his enthusiasm about joining Meditrina, stating, "I am thrilled to be joining Meditrina as the Senior Vice President of Global Sales. I am also incredibly eager to collaborate with our talented team to advance our mission of transforming healthcare through groundbreaking solutions. The Aveta System is a leap forward in technology and I feel privileged to be part of its growth as we drive impactful change in the lives of women."
With Ray at the helm of global sales operations, Meditrina is primed to seize emerging market opportunities and cement its reputation as a trailblazer in hysteroscopy innovation.
About Meditrina:
Founded in 2016, Meditrina, Inc. designs and develops innovative medical devices for minimally invasive gynecology. For more information, visit www.avetasystem.com.
Contact:
Abbey Taylor
Associate VP of Marketing
abbeyt@meditrina-inc.com
Aveta® is a registered trademark of Meditrina, Inc.
SOURCE Meditrina, Inc.
Meditrina, Inc. completes $10M equity financing led by Deerfield
SAN JOSE, Calif., June 1, 2020 /PRNewswire/ -- Meditrina, Inc., a premier women's healthcare company and developer of the state-of-the-art Aveta™ System, for the treatment of intrauterine pathologies such as polyps, fibroids, and/or RPOC, announced today that it has completed a $10 million equity financing as a first tranche of a $20- million commercialization round. The financing was led by Deerfield Management Company. Steven Hochberg, a Partner at Deerfield, will join the Meditrina Board of Directors.
"We are very excited about the potential of the Aveta System which allows for full control of procedures by integrating resection devices with a fluid management system, providing more accuracy and procedural efficiency in comparison to the alternative approaches," said Mr. Hochberg.
Meditrina's Aveta™ System was developed by entrepreneurs with a history of developing leading products in various healthcare fields, including, but not limited to, the EnSeal® tissue sealing devices, the Symphion® bi-polar tissue resection device, and the Minerva endometrial ablation system.
"The Aveta System was designed with full flexibility and scalability to perform various procedures in any setting, whether in an operating room or in a physician's office," said Csaba Truckai, President and CEO of Meditrina. "For the first time, fully integrated electronic hysteroscopes and resection devices have been developed for single use, which is a key differentiator from other decades-old technologies on the market. Single-use systems will greatly reduce the chance of infectious disease cross-contamination that can arise from re-usable hysteroscopes. We believe our single-use systems will provide significant clinical benefits, as well as lower the costs of diagnostic and therapeutic procedures," added Mr. Truckai.
"The Aveta System distances itself over the competition given the direct operator control of distending fluid flow and pressure in the operative field, along with a camera system that continually self-corrects the orientation of the surgical field. The resection blade is second to none in its efficiency and speed of excising difficult to remove myomas," said Dr. Steve Balaloski, OBGYN at WomanKind Obstetrics and Gynecology in Columbus, Ohio.
"Once you experience the Aveta System in a hysteroscopic surgery, it is hard to go back to using the old systems. It is a truly innovative product that is far more effective and efficient than the other competing products which I have used for years. My staff and I find so much less frustration with set-up and implementation as well," said Dr. Elizabeth Coronado, OBGYN Women's Specialists of Plano, Texas.
Abnormal uterine bleeding (AUB) is a common gynecologic problem, estimated to affect up to 30% of women.¹ Endometrial polyps are common, affecting 7.8%–41% of women occurring in premenopausal and postmenopausal women,² and approximately 25% to 50% of women with fibroids are symptomatic.³
Meditrina will use the proceeds from the financing to expand U.S. commercialization of the Aveta™ System and to further develop its product portfolio.
About Deerfield Deerfield is a healthcare investment management firm committed to advancing healthcare through investment, information and philanthropy.
About Meditrina, Inc. Founded in 2016, Meditrina, Inc. designs and develops innovative medical devices for minimally invasive gynecology. For more information, visit www.avetasystem.com.
Contact:Abbey Taylor
Director, Clinical Marketing
abbeyt@meditrina-inc.com
SOURCE Meditrina, Inc.
1 Arnold, Amy & Ketheeswaran, Ashradha & Bhatti, Mominah & Nesbitt-Hawes, Erin & Abbott, Jason. (2016). A Prospective Analysis of Hysteroscopic Morcellation in the Management of Intrauterine Pathologies. Journal of Minimally Invasive Gynecology. 23. 10.1016/j.jmig.2016.01.013.
2 Lee, S.C., Seibel, B. & Kaunitz, A.M. When Should Endometrial Polyps Be Treated?. Curr Obstet Gynecol Rep 1, 89–93 (2012).
3 Marsh, E. E., Al-Hendy, A., Kappus, D., Galitsky, A., Stewart, E. A., & Kerolous, M. (2018). Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women. Journal of women's health (2002), 27(11), 1359–1367.
Addressing the COVID-19 Pandemic and the Impact on Hysteroscopic Procedures with the Aveta System
Keeping aligned with the recommendations for hysteroscopic procedures during and after the COVID-19 pandemic, stated by the Global Congress of Hysteroscopy Scientific Committee, is a priority to Meditrina Inc. Being able to treat all patients experiencing symptoms of abnormal uterine bleeding due to benign intrauterine pathologies is important during these challenging times.
The Aveta™ System, is a new mechanical hysteroscopy system intended for the removal and/or retrieval of intrauterine tissue such as, endometrial polyps, intrauterine fibroids, and/or RPOC, and provides “sterilization free” diagnostic and operative hysteroscopy because all devices are sterile and single use, minimizing set-up time, personnel requirements, and risks associated with cross contamination.
Our unique system can be used in any procedure room whether it’s in the hospital (no in-patient bed, operating suite, video tower, boom, etc. is necessary), ASC, or in-office, our system is easily adaptable to any room. We provide HD Video, superior fluid waste management, and tissue resection all controlled by one compact control box which is mounted onto a single rolling, adjustable saline pole with locking wheels.
We have two sizes of sterile single use Hysteroscopes and Resecting Devices available, dependent on patient comfort and tissue type. Our Hysteroscopes provide the largest working channel with the smallest insertion diameter, 4.6mm OD (3mm ID) and 5.7mm OD (4mm ID), respectively.
Aveta can also be used as a stand-alone fluid management system when used with any standard diagnostic or operative hysteroscope. Additionally, our proprietary sterile single use Hysteroscope can be used with a hanging bag for fluid management. The Aveta System is truly versatile and adaptable to any procedure room, and the surgeon control allows minimal staff when limited resources and PPE are not available.
One of the most overlooked steps during the process of decontaminating and reprocessing of reusable hysteroscopes is pre-cleaning. The steps for cleaning, high-level disinfection (HLD), rinsing, drying and storage for reusable hysteroscopes starts in the procedure room immediately post-op, not in the sterile processing department (SPD), due to having to remove patient biomaterials before biofilm hardening occurs. Proper training is involved to follow the manufacturer’s instructions for use and often takes multiple pages and hours just for the soaking portion of the process. When your staff is limited and/or new, there are a shortage of scopes, and patient turnaround is the highest importance, these steps for scope reprocessing can be burdensome, but are still necessary and required per the manufacturer’s IFU. Even missing one step can render the entire process ineffective and increase the risk of infection transmission. The Aveta System offers you and your patient the comfort of knowing that after each use devices can be easily discarded, eliminating the risk of device-related cross contamination.
In-Office Hysteroscopy Recommendations
Pre-procedure:
• The Aveta System is mechanical which means it does not produce surgical smoke during the case
• Our system contains HD Hysteroscopy video and monitor, fluid waste management and tissue resection on one rolling saline pole
• Our system has integrated inflow and suction outflow for tissue and fluid waste management, no external devices needed to perform hysteroscopy procedures
• Only one/two resources needed in the procedure room since Physician has full control of procedure, can be done with one person, if necessary, during COVID-19 pandemic (less PPE needed)
Intra-procedure:
• Can be done under local/regional anesthesia or conscious sedation due to smaller insertion diameter hysteroscopes available (patient dependent)
• The Aveta System has 5x* faster resection than currently marketed tissue removal devices making it a highly effective option
Post-procedure:
• Rapid procedure turnover because we provide multiple sizes of sterile single use devices that can be easily discarded immediately post-op which means less time needed for room decontamination. Patient can remain in same room with comfort and ease.
• No pre-cleaning, high level disinfection, rinsing, drying, storage required because we provide sterile single use hysteroscopes and resecting devices
Operating Room Hysteroscopy Recommendations
Pre-procedure:
• Aveta System is adaptable to any procedure room in the Hospital or ASC – no boom, surgical monitor, video towers, reusable scopes, light post adaptors or light sources needed to carry out procedures.
• Our system contains HD video, surgical monitor, fluid waste management and tissue resection on one rolling adjustable saline pole
• Only one/two resources needed in the operating room since Physician has full control of procedure, can be done with one person, if necessary, during COVID-19 pandemic (less PPE needed). Can be done on outpatient basis.
Intra-procedure:
• Can be done under local/regional anesthesia or conscious sedation due to smaller insertion diameter hysteroscopes available (patient dependent)
• The Aveta System has 5x* faster resection than currently marketed tissue removal devices making it a highly effective option
• The Aveta System is mechanical which means it does not produce surgical smoke during the case
• Our system has integrated inflow and suction outflow for tissue and fluid waste management, no external devices needed to perform hysteroscopy procedures
Post-procedure:
• Rapid operating room turnover because we provide multiple sizes of sterile single use devices that can be easily discarded immediately post-op which means less time needed for room decontamination.
• No pre-cleaning, high level disinfection, rinsing, drying, storage required because we provide sterile single use hysteroscopes and resecting devices
During the COVID-19 pandemic, patients are being limited to those whom delaying the procedure could result in adverse clinical outcomes. Why limit to only these patients when there are still patients who are seeking relief from their symptoms immediately? You can treat all patients during this challenging time (and after) because the Aveta System can adapt to any procedure room, not taking up inpatient beds, and can be done on an outpatient, same-day discharge. Most diagnostic and operative hysteroscopy procedures can be done under local/regional anesthesia or conscious sedation using our small insertion diameter Aveta Resecting Hysteroscopes.
Set up a virtual demonstration or email us at info@meditrina-inc.com for more information. We look forward to helping you during this time to treat all your patients, in all settings.
*Comparison of Tissue Resection Rates of The Myosure, Truclear, And Aveta Hysteroscopic Tissue Removal Systems. A Three-Arm, Bench Study. A.I. Brill
©2020 Meditrina, Inc. or its affiliates. Aveta™ is a registered trademark of Meditrina, Inc. All rights reserved.
Meditrina to Introduce Aveta™ System for Diagnostic and Therapeutic Hysteroscopy at 2019 AAGL
SAN JOSE, Calif., Nov. 8, 2019 /PRNewswire/ -- Meditrina, Inc. will launch the Aveta™ Hysteroscopy System at the 2019 American Association of Gynecologic Laparoscopists meeting.
The Aveta™ System is a new hysteroscopy platform that combines HD video, fluid management and tissue resection into one seamless system
SAN JOSE, Calif., Nov. 8, 2019 /PRNewswire/ -- Meditrina, Inc. will launch the Aveta™ Hysteroscopy System at the 2019 American Association of Gynecologic Laparoscopists meeting.
The Aveta™ hysteroscopy suite was designed to provide physicians with the best care in their diagnosis and treatment of endometrial polyps and uterine fibroids. The system seamlessly integrates into any operating, procedure, or exam room. This new hysteroscopy system is an all-in-one platform which includes the single-use Aveta™ Pearl Hysteroscope for myomectomy, and the single-use Aveta™ Coral Hysteroscope for polypectomy procedures with integrated tissue resection and fluid management capability. The Aveta™ Pearl Hysteroscope is the first single-use hysteroscope to include full physician control providing proprietary fluid management and video control function directly on the hysteroscope handle.
Both HD wide field of view Aveta™ Hysteroscopes include patented expandable working channel technology providing the largest working channel with the smallest insertion diameter on the market. Additionally, both Hysteroscopes contain a proprietary image orientation lock feature which constantly keeps the image in an upright position, thus eliminating awkward tubing, light cable, and camera head management, while ensuring a consistent frame of reference and ease of use for the physician, with minimal patient discomfort. The simplified setup of the integrated fluid management was designed to facilitate the nursing staff in supporting procedures with ease and reduce OR setup time. The Aveta™ Fluid Management was also cleared by the FDA to be used as a standalone fluid management system with selected standard hysteroscopes.
The proprietary Aveta™ 3.9mm Resecting Device, is capable of removing over 20g/min of fibroid tissue,¹ and Monday, November 11th at 12:17pm, Dr. Andrew Brill, will present, Comparison of Tissue Resection Rates of The MyoSure, TruClear, and Aveta Hysteroscopic Tissue Removal Systems. A Three-Arm, Bench Study, during Open Communications 3 Hysteroscopy, at the 2019 AAGL Meeting.
About Meditrina, Inc.
Founded in 2016, Meditrina, Inc. is a small research and development engineering startup which designs and develops innovative medical devices for minimally invasive gynecology. For more information, visit www.avetasystem.com.
References
1. Comparison of Tissue Resection Rates of the Myosure, Truclear, and Aveta Hysteroscopic Tissue Removal Systems. A ThreeArm, Bench Study
Brill, AI
Journal of Minimally Invasive Gynecology, Volume 26, Issue 7, S29 - S30
